Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5 - Quantum BioPharma (NASDAQ:QNTM)
TORONTO, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Quantum BioPharma Ltd. ( NASDAQ:QNTM ) ( CSE:QNTM ) ( FRA: 0K91 ) ( "Quantum BioPharma" ) , is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a three-part series about Quantum ...
How this was made

The 30-second read
Why it matters
The media coverage and legal allegations are likely to induce short-term negative sentiment, increasing volatility and downward pressure on the stock.
Market read
The news is highly relevant for traders holding or considering trading QNTM, especially in the short term.
What to watch
Potential positive developments or settlement could lead to a rapid rebound.
Background
Quantum BioPharma is facing a USD $700 million lawsuit alleging stock market manipulation, which has attracted media attention and could influence investor sentiment.
Ticker impact
High relevance due to direct involvement in the lawsuit and media coverage.
Potential short-term decline of 5-10%, with increased volatility.
Legal actions and media scrutiny typically exert downward pressure, but the impact depends on case developments and market perception.
Market effects
Potential negative sentiment affecting biotech and pharmaceutical sectors.
Limited regional impact, primarily affecting North American markets.
Moderate, as Quantum BioPharma is a NASDAQ-listed company with international investors.
Counterpoint
Legal issues may be overblown, and the company could recover quickly if no substantive evidence is found.
Key entities
- CompanyQuantum BioPharma Ltd.
A biotechnology company listed on NASDAQ, involved in legal proceedings.




